Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019001417) IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/001417 International Application No.: PCT/CN2018/092827
Publication Date: 03.01.2019 International Filing Date: 26.06.2018
IPC:
C07K 16/28 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
WANG, Lai [US/CN]; CN (SC)
BEIGENE, LTD.; c/o Mourant Ozannes Corporate Services (Cayman) Limited 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, KY
Inventors:
WANG, Lai; CN
LI, Kang; CN
QI, Qinzhou; CN
HOU, Jeannie; US
WU, Zhong; US
Agent:
WU, FENG & ZHANG; 3 FL, Building 2, Yard 3 FengXiuZhongLu Road, Haidian District Beijing 100094, CN
Priority Data:
62/524,96726.06.2017US
PCT/CN2017/09039727.06.2017CN
Title (EN) IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
(FR) IMMUNOTHÉRAPIE POUR CARCINOME HÉPATOCELLULAIRE
Abstract:
(EN) Disclosed herein is method for the prevention, delay of progression or treatment of hepatocellular carcinoma in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of an anti-PD-1 antibody, which is an antibody or a fragment antigen binding thereof, specifically binding to human PD-1.
(FR) L'invention concerne un procédé pour la prévention, le retard de progression ou le traitement d'un carcinome hépatocellulaire chez un sujet, comprenant l'administration au sujet en ayant besoin d'une quantité efficace sur le plan thérapeutique d'un anticorps anti-PD-1, qui est un anticorps ou un fragment d'antigène de liaison à celui-ci, se liant de manière spécifique à PD-1 humain.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)